Latest news

• Merck claims first-ever okay for Ebola vaccine, in Europe

  The approval comes shortly after Johnson &Johnson  filed its Ebola vaccine candidate (Ad26.ZEBOV, MVA-BN-Filo) with the EMA, setting up a possible approval next year, and ahead of a ... To date, hundreds of thousands of people have been vaccinated

• J&J catches up to Merck, files Ebola vaccine in Europe

  The company has submitted two MAAs to the EMA in parallel, to support each vaccine in a two-dose regimen (Ad26.ZEBOV, MVA-BN-Filo). ... The regimen is delivered through a first dose of Ad26.ZEBOV and MVA-BN-Filo as the second dose, approximately eight

• Merck wins CHMP recommendation for Ebola vaccine

  However, Merck is most likely to be the first to obtain formal regulatory approval for an Ebola vaccine, as J&J’s Ad26.ZEBOV and another candidate called MVA-BN-Filo

• FDA starts speedy review of Merck’s Ebola vaccine

  Merck is out in front when it comes to getting formal approval for an Ebola vaccine, as J&J’s Ad26.ZEBOV and another candidate called MVA-BN-Filo from Bavarian

• HIV vaccine from J&J starts human trials

  In the case of J&J's vaccine, the regimen is an adenovirus serotype 26 (Ad26) vectored vaccine to prime the immune system, followed by a boost with a purified HIV